Stockholm - Delayed Quote SEK

Klaria Pharma Holding AB (publ.) (KLAR.ST)

0.4100
-0.0100
(-2.38%)
At close: June 13 at 5:23:25 PM GMT+2

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
NameTitlePayExercisedYear Born
Mr. Scott Boyer CEO & Director 1.91M -- 1962
Mr. Hans Richter Chief Financial Officer -- -- 1949
Mr. Marc Willuhn Ph.D. Head of Chemistry, Manufacturing & Control -- -- 1969
Dr. Hans Olivecrona M.D., Ph.D. Chief Medical Officer -- -- 1958

Klaria Pharma Holding AB (publ.)

Virdings AllE 2
Uppsala, 754 50
Sweden
46 84 46 42 99 https://www.klaria.com
Sector: 
Healthcare
Full Time Employees: 
4

Description

Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, as well as opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction; and Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. Further, the company engages in the commercialization of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is headquartered in Uppsala, Sweden.

Corporate Governance

Klaria Pharma Holding AB (publ.)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers